The researchers suggested that NKCC1 activity in TMZ-treated cells was stimulated via Cl−/volume-sensitive regulatory kinases and the WNK-mediated signaling pathway, which is vital in protecting glioma from a loss of cell volume and Cl− during TMZ treatment. This evidence concerns the gene SLC12A2 and central nervous system cancer.